GSK stop clinical trial of NPS PTH agent Ronacaleret « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
September 2008

M T W T F S S

« Aug Oct »

1 2 3 4 5 6 7

8 9 10 11 12 13 14

15 16 17 18 19 20 21

22 23 24 25 26 27 28

29 30

GSK stop clinical trial of NPS PTH agent Ronacaleret

Posted on September 26, 2008 by crimsoncanary

NPS Pharmaceuticals have announced that its partner GlaxoSmithKline have decided to prematurely stop a mid-stage study of PTH agent Ronacaleret in post-menopausal women with osteoporosis due to an observed lack of efficacy.

Filed under: Uncategorized | Tagged: GlaxoSmithkline, GSK, NPS, Parathyroid, PTH, Ronacaleret

« CHMP recommends approval of olanzapine LAI for maintenance therapy in schizophrenai Watsons solidosin effective in BPH »

Leave a Reply